Physician profile
Thomas C Wall
NPI 1528018314
$2,530.89
in general payments reported to CMS, 2019-2025
22 companies · $658 in 2025
The $658 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $93.91 · 2021: $127 · 2022: $233 · 2023: $428 · 2024: $992 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,058 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,057.63 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $469.85 | 2020-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $361.87 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $313.45 | 2020-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $267.36 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $244.56 | 2023-2025 | |
| Medtronic, INC. | $110.47 | 2022 | |
| Pfizer INC. | $100.01 | 2022-2025 | |
| Glaxosmithkline, LLC. | $87.36 | 2023-2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $78.52 | 2025 | |
| Phathom Pharmaceuticals, INC. | $78.32 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $54.19 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.34 | 2021-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $49.82 | 2021-2023 | Trintellix |
| Mylan Specialty L.P. | $46.60 | 2023-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $40.11 | 2024 | Eliquis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $33.99 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.68 | 2025 | Caplyta |
| Lexicon Pharmaceuticals, INC. | $29.04 | 2024 | |
| Sumitomo Pharma America, INC. | $28.06 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $20.93 | 2021 | |
| Depuy Synthes Sales INC. | $17.57 | 2024 | Orthovisc |
| Vertos Medical, INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.